Milestone payment of $10 million triggered under the global license agreement with TakedaLEXINGTON, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that the first patient was dosed in the ...

Corporate Presentation January 2025 Disclaimer Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "anticipates," "believes," "expects," "intends," "plans," "potential," "projects," "would" and "future" or similar expressions are intended to identify forward-looking statements. Examples of these forward-looking statements include stateme ...

Significant Withhold Votes from Directors Mary Ann Gray and Alpna Seth Underscores Need for Change and a More Disciplined Capital Allocation StrategyAUSTIN, Texas, June 9, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1" or "We"), the largest stockholder of Keros Therapeutics (Nasdaq: KROS) ("Keros" or the "Company"), today issued the following statement regarding the results of the Company's 2025 Annual Meeting of Stockholders (the "Annual Meeting"):"We believe the ...

Keros Therapeutics (KROS) FY 2025 Conference June 09, 2025 09:20 AM ET Speaker0 Thanks for joining us here at the Goldman Sachs Global Healthcare Conference. We are joined today on stage by Jas from KAROS, and maybe we will kick it off just kind of an overview. So I'd love if you could provide kind of an overview of KAROS as it stands today, recognizing there were some new news as well this morning. And can you focus also on what you see as sort of the value drivers of the company over the next, let's say, ...

Concludes Strategic Alternatives Review and Provides Update on Development of KER-065LEXINGTON, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that the Company has concl ...

Core Insights - Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting disorders linked to dysfunctional signaling of the TGF-ß protein family [3] Company Overview - Keros is recognized as a leader in understanding the TGF-ß family of proteins, which are crucial for the growth, repair, and maintenance of various tissues, including blood, bone, skeletal muscle, adipose, and heart tissue [3] - The company's lead product candidate, KER-065, is aimed at treating neuromuscular diseases, specifically Duchenne muscular dystrophy [3] - Keros' most advanced product candidate, elritercept (KER-050), is being developed for treating cytopenias, such as anemia and thrombocytopenia, in patients with myelodysplastic syndrome and myelofibrosis [3] Upcoming Events - Keros' Chair and CEO, Jasbir S. Seehra, Ph.D., will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025, at 9:20 a.m. Eastern time [1] - A live audio webcast of the presentation will be available, with an archived replay accessible for up to 90 days post-event [2]

Core Viewpoint - Keros Therapeutics has decided to discontinue the development of cibotercept for pulmonary arterial hypertension (PAH) following safety concerns and will undergo corporate restructuring to align with strategic priorities [1][3][5]. TROPOS Trial Results - The TROPOS trial was a Phase 2 clinical trial evaluating cibotercept in combination with background therapy for PAH, which was halted due to observed adverse events, specifically pericardial effusions [2][7]. - The company voluntarily stopped dosing in all treatment arms of the trial after safety reviews indicated new adverse events [2]. Corporate Restructuring - Keros plans to reduce its workforce by approximately 45%, resulting in a total of 85 full-time employees, which is expected to yield annualized cost savings of about $17 million [5][6]. - The restructuring is aimed at aligning operations with ongoing development programs and maximizing stockholder value [6]. Future Development Strategy - The company will evaluate the potential development of cibotercept for other indications after completing a strategic alternative review process [4][6]. - Keros is also exploring various strategic alternatives, including potential sale or business combinations, continued investment in its pipeline, and returning excess capital to stockholders [6]. Company Overview - Keros Therapeutics focuses on developing therapeutics targeting disorders linked to dysfunctional signaling of the TGF-ß family of proteins, with lead candidates including KER-065 for neuromuscular diseases and elritercept for cytopenias [8].

Core Viewpoint - Keros Therapeutics emphasizes the importance of its board in overseeing the strategic review process and urges stockholders to support its director nominees to maximize company value amid challenges posed by ADAR1's campaign [1][2][3]. Company Overview - Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting disorders linked to dysfunctional signaling of the TGF-ß protein family [10][11]. - The company is advancing several product candidates, including cibotercept for pulmonary arterial hypertension, KER-065 for neuromuscular diseases, and elritercept for cytopenias [10][11]. Board Composition and Strategy - The Keros Board consists of nine independent directors, including four stockholder representatives, bringing diverse expertise in biotechnology, drug development, and capital allocation [7]. - The board is currently engaged in a strategic alternatives review process, which is seen as a constructive step to address shareholder concerns and maximize value [3][8]. Proxy Advisory Firm Recommendations - Glass Lewis & Co. has recommended that Keros stockholders vote "FOR" all three of the company's director nominees, recognizing their qualifications and the board's efforts to enhance stockholder value [1][3]. - The board's decision to retain flexibility through a formal strategic review is viewed as a reasonable approach, contrasting with ADAR1's aggressive campaign [3][5]. Response to ADAR1's Campaign - Keros has responded to claims made by ADAR1, stating that the recent share price decline is primarily due to clinical development risks rather than board mismanagement [3][4]. - The company argues that ADAR1 has not provided compelling evidence against the board members and that the board's actions have been in the best interests of all stockholders [3][6].

ADAR1 Urges Board to Release Strategic Review Results Before, Not After, Annual Meeting ADAR1 Capital Management is an SEC-registered investment manager based in Austin, Texas, focused on public and private equity investments in the life sciences and biotechnology sectors. The firm was founded in October 2018 by Dr. Daniel Schneeberger, who brings over 20 years of experience spanning scientific research, healthcare consulting, institutional investing, and executive leadership in the healthcare industry. He ...

Summary of Keros Therapeutics and Tiara Biosciences Conference Calls Keros Therapeutics (KROS) Industry Overview - Keros Therapeutics focuses on the TGF beta pathway, which is crucial for embryogenesis and tissue maintenance. Dysregulation of this pathway is linked to various diseases [3][4]. Core Pipeline - Keros has three main assets: 1. **Aridrocept 50**: A ligand trap for MDS and myelofibrosis, partnered with Takeda, showing promising economics [5]. 2. **Cibodocept**: A trial for pulmonary arterial hypertension (PAH) was terminated early due to safety signals, with top-line data expected soon to determine the next steps [6][10]. 3. **A third ligand trap**: Targets negative regulators of skeletal muscle, enhancing muscle regeneration and improving bone mineral density, suitable for neuromuscular indications [6][7]. Financial and Strategic Challenges - An activist investor has challenged Keros' leadership, prompting the company to explore strategic alternatives to maximize pipeline value [8][10]. - The stock has declined below cash levels, leading to a reassessment of the company's strategy [10]. Clinical Development Insights - Aridrocept is in a Phase 3 trial for MDS, with potential annual sales projected to reach $2 billion if approved for frontline treatment [15][16]. - The company aims to demonstrate that Cibodocept can be effective in PAH, despite recent safety concerns [22][23]. - The CEO emphasizes the importance of patient quality of life and transfusion independence in treatment outcomes [19][21]. Tiara Biosciences Industry Overview - Tiara focuses on small molecule precision medicines, particularly in the FGFR family, with a lead molecule that is FGFR3 selective [34][35]. Unique Platform - The Snap Chemistry Design Platform allows for the development of selective FGFR3 inhibitors, differentiating Tiara from other developers that use pan FGFR inhibitors [35][36]. Clinical Development and Market Potential - Tiara is addressing unmet needs in non-muscle invasive bladder cancer (NMIBC) and achondroplasia, with a focus on oral therapies that can reduce recurrence rates compared to current treatments [39][40]. - The company anticipates generating top-line results from ongoing trials, with a focus on complete response rates as early efficacy signals [44][45]. Competitive Landscape - Tiara's FGFR3 inhibitor is positioned to have a better safety profile compared to existing therapies, with lower rates of adverse effects such as nail toxicity and stomatitis [56][57]. - The company aims to exceed existing benchmarks for height velocity in achondroplasia treatments, targeting an annualized height velocity of 8-8.5 cm [62][53]. Financial Position - Tiara is well-capitalized, with sufficient funds to support operations through 2027, allowing for strategic prioritization of its clinical programs [64][65]. Conclusion - Both Keros Therapeutics and Tiara Biosciences are navigating complex clinical landscapes with innovative therapies aimed at significant unmet medical needs. Keros is focusing on maximizing the value of its pipeline amidst strategic challenges, while Tiara is leveraging its unique platform to differentiate itself in the FGFR inhibitor market.